As of June 2026, according to Iradimed's latest financial report, the company's current EPS (TTM) is $1.86. Iradimed's EPS for 2025 came in at $1.77, marking an increase from $1.52 in 2024. Iradimed's earnings per share for the quarterly report ending on Mar 31, 2026 was $0.46.
The annual EPS in 2025 was $1.77, an increase of 16.4% from $1.52 in 2024. The quarterly EPS for the period ending Mar 31, 2026, was $0.46, marking a 24.3% increase from the same quarter last year. IRMD's TTM EPS stands at $1.86 as of March 2026. Iradimed's EPS for 2024 stood at $1.52, a 11.8% increase from 2023.
Iradimed has recorded an increase in EPS of 24.3% over the last 12 months (YoY, quarterly). For the last three years, IRMD recorded an average annual EPS growth rate of 20.2%. Iradimed had an average annual EPS growth rate of 71.3% over the last 5 years. Across the last decade, IRMD had an average annual EPS growth of 10%.
| Stock name | Price to Earnings | EPS grwoth 1Y | EPS grwoth 3Y | EPS grwoth 5Y |
|---|---|---|---|---|
| DXCM Dexcom Inc | 30.25 | 46.6% | 34.5% | 7.9% |
| COO Cooper Companies Inc | 31.04 | -4.6% | -1.2% | 9.2% |
| EW Edwards Lifesciences Corp | 46.26 | -73.6% | -9.2% | 6.9% |
| IRMD Iradimed Corp | 50.31 | 16.4% | 20.2% | 71.3% |
All data is based on quarterly TTM periods, unless otherwise specified.